← Patent-cliff monitor small molecule IMBRUVICA IBRUTINIB
Loss of exclusivity June 2039 latest FDA-listed patent expiry
Drug detail Brand name IMBRUVICA Active ingredient IBRUTINIB Strength 70MG/ML Dosage form SUSPENSION Route ORAL Modality Small molecule FDA approval August 2022 Marketing status RX
Listed patents Patent Expires Type 12201690 June 2039 product 12364698 April 2036 product 9795604*PED April 2035 — 10695350 October 2034 use U-2970 10463668 October 2034 use U-2970 9795604 October 2034 use U-2970 9296753*PED April 2034 — 9725455*PED December 2033 — 10961251*PED December 2033 — 10125140*PED December 2033 — 10106548*PED December 2033 — 9296753 October 2033 substance 9725455 June 2033 substance 10106548 June 2033 substance, product 10125140 June 2033 substance, product 10961251 June 2033 product 10478439*PED December 2031 — 10016435 June 2031 use U-3845 10478439 June 2031 use U-3845 8999999 June 2031 use U-3844 9125889 June 2031 use U-3845 9801881 June 2031 use U-3847 9801883 June 2031 use U-3844 10004746 June 2031 use U-3847 10751342 June 2031 use U-3842 11672803 June 2031 use U-3843 8008309*PED May 2028 — 8008309 November 2027 substance, product 9181257*PED June 2027 — 8754091*PED June 2027 — 8735403*PED June 2027 — 8497277*PED June 2027 — 7514444*PED June 2027 — 8697711*PED June 2027 — 8957079*PED June 2027 — 8563563 April 2027 use U-3845 8735403 December 2026 substance, product 8754091 December 2026 product 7514444 December 2026 substance, product 9181257 December 2026 substance 8697711 December 2026 substance, product 8957079 December 2026 substance, product 8497277 December 2026 use U-2970 8476284 December 2026 use U-3845 8952015 December 2026 use U-3845 8703780 December 2026 use U-3842
Regulatory exclusivity Code Expires PED February 2030 ODE-405 August 2029 PED February 2026 NP August 2025
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.